StreetInsider.com News Articles

Form SCHEDULE 13G FEMASYS INC Filed by: Empery Asset Management, LP

Thu, 15 Oct 2026 12:32:00 -0400

si-local-file:///var/storage/secattach/20261015/27192338.html

Femasys Doubles Enrolling Sites in FemBloc FINALE Pivotal Trial for Non-Surgical Permanent Birth Control

Wed, 14 Oct 2026 09:00:00 -0400

-- Twelve academic and private clinical sites across the U.S. broaden patient access to the pivotal trial as Femasys advances FemBloc toward potential FDA approval --

ATLANTA, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announced today that it has doubled the number of actively enrolling sites in its FemBloc^® FINALE Pivotal Trial to twelve across the United States. The coast-to-coast network of academic centers and

Femasys Doubles Enrolling Sites in FemBloc FINALE Pivotal Trial for Non-Surgical Permanent Birth Control

Wed, 14 Oct 2026 09:00:00 -0400

-- Twelve academic and private clinical sites across the U.S. broaden patient access to the pivotal trial as Femasys advances FemBloc toward potential FDA approval --

Femasys to Exhibit at the ASRM 2026 Scientific Congress & Expo

Thu, 08 Oct 2026 09:00:00 -0400

ATLANTA, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announced today that it will exhibit at the American Society for Reproductive Medicine (ASRM) 2026 Scientific Congress & Expo, taking place October 24–28 at the Baltimore Convention Center in Baltimore, Maryland. The Company will highlight FemaSeed® Intratubal Insemination (ITI), a first-step fertility treatment option, together with FemVue®, its complementary diagnostic solution for in-office fallopian tube

Femasys to Exhibit at the ASRM 2026 Scientific Congress & Expo

Thu, 08 Oct 2026 09:00:00 -0400

Femasys to Exhibit at the ASRM 2026 Scientific Congress & Expo

Thu, 08 Oct 2026 09:00:00 -0400

Continued participation underscores commitment to expanding options for patients referred to fertility centers under the care of reproductive endocrinologists

Femasys to Exhibit at the ASRM 2026 Scientific Congress & Expo

Thu, 08 Oct 2026 09:00:00 -0400

Continued participation underscores commitment to expanding options for patients referred to fertility centers under the care of reproductive endocrinologists

Form 424B3 FEMASYS INC

Tue, 29 Sep 2026 07:03:00 -0400

si-local-file:///var/storage/secattach/20260929/27117259.html

Form EFFECT FEMASYS INC

Tue, 29 Sep 2026 06:05:00 -0400

si-local-file:///var/storage/secattach/20260929/27116860.html

Femasys Advances OB/GYN Expansion with Adoption of FemaSeed® Fertility Portfolio by Minnesota Women’s Care

Tue, 15 Sep 2026 09:00:00 -0400

-- Leading multi-site OB/GYN health practice to implement FemVue^® for fertility diagnostic evaluation and FemaSeed for first-line treatment across all four locations --

ATLANTA, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announced today that Minnesota Women’s Care will implement FemVue for fertility diagnostic evaluation and FemaSeed Complete for in-office first-line fertility treatment across its four OB/GYN practice locations.

Femasys Advances OB/GYN Expansion with Adoption of FemaSeed® Fertility Portfolio by Minnesota Women’s Care

Tue, 15 Sep 2026 09:00:00 -0400

-- Leading multi-site OB/GYN health practice to implement FemVue^® for fertility diagnostic evaluation and FemaSeed for first-line treatment across all four locations --

Femasys Partners with CapexMD to Expand Patient Access to FemaSeed® Fertility Portfolio

Wed, 09 Sep 2026 09:00:00 -0400

Collaboration provides dedicated patient financing for Femasys fertility solutions, helping reduce financial barriers to care across OB/GYN practices and fertility centers

ATLANTA, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announced today a partnership with CapexMD to expand patient access to its FemaSeed-led fertility portfolio through dedicated financing solutions. The partnership will support access to FemaSeed Complete, an in-office intratubal insemination solution designed

Femasys Partners with CapexMD to Expand Patient Access to FemaSeed® Fertility Portfolio

Wed, 09 Sep 2026 09:00:00 -0400

Collaboration provides dedicated patient financing for Femasys fertility solutions, helping reduce financial barriers to care across OB/GYN practices and fertility centers

Femasys partners with UNC Health to expand fertility portfolio

Wed, 26 Aug 2026 09:01:16 -0400

Femasys Inc. (NASDAQ: FEMY) announced a partnership with UNC Health to introduce its fertility diagnostics and treatment products across UNC Health's OB/GYN practice locations in North Carolina, according to a company press release.

The agreement covers FemVue, a fallopian tube patency assessment tool using ultrasound; SpermVue, an at-home male fertility screening option; and FemaSeed Complete, an in-office intratubal insemination solution intended as a first-line fertility treatment. OB/GYNs within the UNC Health system will be able to offer these products without requiring referral to a fertility specialist or outside laboratory.

Femasys CEO and Founder Kathy Lee-Sepsick said the company launched its OB/GYN commercial

Femasys Partners with UNC Health to Introduce Its FemaSeed® Fertility Portfolio Across Statewide OB/GYN Care Locations

Wed, 26 Aug 2026 09:00:00 -0400

-- For the first time, OB/GYNs within the UNC Health system will be able to offer women FemVue^® fertility evaluation and FemaSeed as a first-line treatment option --

ATLANTA, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announced today a partnership with UNC Health to introduce its female and male fertility diagnostics, FemVue and SpermVue™, together with FemaSeed Complete,

Femasys Partners with UNC Health to Introduce Its FemaSeed® Fertility Portfolio Across Statewide OB/GYN Care Locations

Wed, 26 Aug 2026 09:00:00 -0400

-- For the first time, OB/GYNs within the UNC Health system will be able to offer women FemVue^® fertility evaluation and FemaSeed as a first-line treatment option --

Form D FEMASYS INC

Thu, 20 Aug 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260820/26956397.html

Form D FEMASYS INC

Thu, 20 Aug 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260820/26956397.html

FDA approves modular PMA pathway for Femasys FemBloc device

Wed, 19 Aug 2026 09:00:13 -0400

Femasys Inc. (NASDAQ: FEMY) announced that the U.S. Food and Drug Administration has approved a modular premarket approval application (PMA) pathway for FemBloc, the company's investigational non-surgical permanent birth control technology.

The modular PMA approach allows the FDA to review key components of the submission before final clinical data are available. FemBloc is currently being studied in the FINALE pivotal trial and has already received regulatory approvals in Europe, the United Kingdom, and New Zealand.

"FDA approval of the modular PMA pathway provides a clear and efficient framework for advancing FemBloc toward U.S. approval, allowing key components of the submission to be

Femasys Announces FDA Approval of Modular PMA Submission Approach for FemBloc®

Wed, 19 Aug 2026 09:00:00 -0400

-- Modular PMA pathway advances FemBloc toward potential U.S. approval while Femasys builds commercial infrastructure across its reproductive health portfolio --

ATLANTA, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announced today that the U.S. Food and Drug Administration has approved the Company’s modular premarket approval application (PMA) pathway for FemBloc, its investigational non-surgical permanent birth control technology in the United States. FemBloc is approved for

Femasys Announces FDA Approval of Modular PMA Submission Approach for FemBloc®

Wed, 19 Aug 2026 09:00:00 -0400

-- Modular PMA pathway advances FemBloc toward potential U.S. approval while Femasys builds commercial infrastructure across its reproductive health portfolio --

Femasys Inc. (FEMY) PT Lowered to $10 at Lake Street

Tue, 18 Aug 2026 10:49:40 -0400

Lake Street analyst Benjamin Haynor lowered the price target on Femasys Inc. (NASDAQ: FEMY) to $10.00 (from $30.00) while maintaining a Buy rating.

Form SCHEDULE 13D FEMASYS INC Filed by: Nantahala Capital Partners Limited Partnership

Mon, 17 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260817/26938380.html

Form SCHEDULE 13D FEMASYS INC Filed by: Nantahala Capital Partners Limited Partnership

Mon, 17 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260817/26938380.html

Femasys Inc. (FEMY) Misses Q2 EPS by 20c

Mon, 17 Aug 2026 06:39:37 -0400

Femasys Inc. (NASDAQ: FEMY) reported Q2 EPS of ($1.33), $0.20 worse than the analyst estimate of ($1.13). Revenue for the quarter came in at $330 thousand versus the consensus estimate of $1.16 million.

For earnings history and earnings-related data on Femasys Inc. (FEMY) click here.